Introduction {#hyy129s5}
============

The incidence of prostate cancer is less common in Japan when compared with global population, however, aging and western lifestyle have contributed to a gradual increase in the incidence and mortality from prostate cancer in Japanese population in the recent years ([@hyy129C1]--[@hyy129C3]). Men with prostate cancer in Japan are most commonly diagnosed with high-risk characteristics and advanced-stage disease than those in most other developed countries, presumably because of lack of early detection by prostate-specific antigen (PSA) screening ([@hyy129C4]). Patients with newly diagnosed metastatic hormone-naïve prostate cancer (mHNPC), particularly with high-risk features, have a poor prognosis ([@hyy129C5]). In Japan, mHNPC accounts for \~10% of newly diagnosed prostate cancers and castration using androgen-deprivation therapy (ADT) has remained the first choice of treatment ([@hyy129C6]--[@hyy129C8]). The ADT includes bilateral orchiectomy or luteinizing hormone-releasing hormone (LH-RH) analogs, with or without first generation androgen-receptor inhibitors. Although there is an initial clinical benefit with such treatments, most patients eventually become resistant and progress to metastatic castration-resistant prostate cancer (mCRPC) around 1--2 years, despite preserving a low testosterone level ([@hyy129C9]). Novel agents with different mechanisms of action that preserve low androgen levels by further decreasing androgen production or inhibiting the androgen receptor function were later developed to provide additional benefits. A combination of docetaxel and ADT has shown to improve overall survival (OS) benefit in several randomized studies conducted in patients with mHNPC, especially with a high metastatic burden ([@hyy129C10]--[@hyy129C13]). However, patient disease status, comorbidities and patient preferences limit the use of docetaxel. There are currently limited treatment options for the mHNPC in Japan, despite the development of new therapeutic options for mCRPC.

Abiraterone acetate (AA) is the prodrug of abiraterone that blocks the androgen biosynthesis by specifically inhibiting the enzyme cytochrome P-450c17. AA plus prednisone (AAP) along with ADT significantly prolonged OS and was shown to provide other clinical benefits in patients with mCRPC in both pre- and post-chemotherapy setting in the global population ([@hyy129C14]--[@hyy129C18]) and in the Japanese population ([@hyy129C19]--[@hyy129C22]). This treatment is currently approved for mCRPC in \>100 countries, including Japan ([@hyy129C23]), based on the efficacy and safety findings observed in Phase 2 and 3 randomized studies. The addition of AAP to ADT has also shown a reduction in tumor burden in men with high-risk, localized prostate cancer who received neoadjuvant therapy, which suggests its plausible role in inhibiting the extragonadal androgen biosynthesis before it progresses to castration resistance in mHNPC patients ([@hyy129C24],[@hyy129C25]). A Phase 3, multinational, double-blind, placebo-controlled study (LATITUDE) was recently conducted in patients with newly diagnosed mHNPC to evaluate the efficacy and safety of AAP in addition to ADT versus ADT alone. Findings from LATITUDE showed that the addition of AAP to ADT significantly prolonged OS and rPFS compared with ADT alone in men with newly diagnosed mHNPC ([@hyy129C26]). The OS benefit demonstrated with AAP in LATITUDE was confirmed in a recently reported meta-analysis ([@hyy129C27]). The present subgroup analysis of LATITUDE study was performed to evaluate the clinical benefits of combining AAP with ADT in Japanese men with newly diagnosed mHNPC.

Methods {#hyy129s6}
=======

The respective Institutional Review Board approved the study protocol. The study was conducted in accordance with the ethical principles that have their origin in the Declaration of Helsinki and that are consistent with Good Clinical Practices and applicable regulatory requirements. All patients provided written informed consent before enrollment.

Patients {#hyy129s7}
--------

Men aged ≥18 years with newly diagnosed (≤3 months before randomization), pathologically confirmed prostate cancer without neuroendocrine differentiation or small-cell histologic features and with an Eastern Cooperative Oncology Group (ECOG) performance-status score of 0 to 2 (on a 5-point scale, with higher numbers indicating greater disability) were eligible for enrollment. Additionally, patients with high-risk, mHNPC, were enrolled only if they fulfilled 2 of the 3 following high-risk factors: (1) a Gleason score of ≥8, (2) presence of ≥3 bone lesions by positive bone scans and (3) the presence of measurable visceral metastasis on CT or MRI scan (according to Response Evaluation Criteria In Solid Tumors \[RECIST\] version 1.1 criteria).

Patients with a medical condition that would contraindicate prednisone use or require \>5 mg/day of systemic prednisone treatment; significant cardiac, adrenal or liver dysfunction; a significant laboratory abnormality; a malignancy other than prostate cancer or non-melanoma skin cancer within 5 years; previous pharmacotherapy, radiation therapy or surgery for metastatic prostate cancer (with the exception of ≤3 months of ADT or one course of palliative radiation or surgical therapy to treat symptoms associated with metastatic disease) were excluded.

Study design {#hyy129s8}
------------

This was a subgroup analysis of a double-blind, placebo-controlled, Phase 3 study (LATITUDE, NCT01715285); conducted at 235 sites in 34 countries, including Japan. The detailed methodology of the primary study has been published elsewhere ([@hyy129C26]). Briefly, eligible patients were stratified according to the presence or absence of measurable visceral disease and ECOG performance-status score (0 or 1 vs 2) and randomized (1:1) to receive ADT and AA (1000 mg orally once daily, 4 × 250 mg tablets) and prednisone (5 mg daily) (AAP group) or ADT and respective placebos (placebo group), at least 1 h before or 2 h after a meal (Fig. [1](#hyy129F1){ref-type="fig"}). The ADT utilized were LH-RH analogs, or anti-androgens for up to 3 months prior to randomization, but were allowed for only 2 weeks after Cycle 1; or orchiectomy ≤3 months from randomization. Patients without surgical castration received ongoing ADT to maintain serum testosterone levels less than 50 ng/dl.

![Study design. ADT, androgen-deprivation therapy; ECOG, Eastern Cooperative Oncology Group; mHNPC, metastatic hormone-naïve prostate cancer; OS, overall survival; PC, prostate cancer therapy; PSA, prostate-specific antigen; rPFS, radiographic progression-free survival; QD, once daily.](hyy129f01){#hyy129F1}

Efficacy endpoints {#hyy129s9}
------------------

The coprimary efficacy endpoints were OS (time from randomization to death from any cause) and radiographic progression-free survival (rPFS; time from randomization to the occurrence of radiographic progression or death from any cause). Secondary efficacy endpoints were time to pain progression (defined as time from randomization to the first date a patient experiences an increase of \>30% from baseline in the worst pain category on the Brief Pain Inventory--Short Form \[BPI-SF\] as observed at two consecutive evaluations performed \>4 weeks apart), time to PSA progression (on the basis of Prostate Cancer Working Group 2 \[PCWG2\] criteria), time to next skeletal-related event (a clinical or pathological fracture, spinal cord compression, palliative radiation to bone, or surgery involving bone), time to initiation of chemotherapy, and time to the next therapy for prostate cancer.

Efficacy assessments {#hyy129s10}
--------------------

Radiographic progression on bone scanning was assessed based on PCWG2 and progression of soft tissue lesions was evaluated by CT or MRI based on RECIST 1.1; every 4 months from week 16. Survival status and subsequent chemotherapy for prostate cancer were assessed at regular follow-up intervals (of 4 months) up to 60 months or until patient's death, lost to follow-up, withdrawal of consent or study termination. Serum PSA evaluation was performed at baseline, once a month in the first year, then every 2 months until end of treatment.

Safety assessments {#hyy129s11}
------------------

Safety was evaluated based on AEs, vital sign measurements and clinical laboratory tests (hematology, serum chemistry, and liver function tests). AE severity grade was assessed according to the National Cancer Institute (NCI)-Common Terminology Criteria for Adverse Events (CTCAE), Version 4.0.

Statistical methods {#hyy129s12}
-------------------

Statistical analyses for the overall study population are described in the primary publication ([@hyy129C26]). First interim OS analysis and single rPFS analysis was planned after observing \~50% (426 events) of the total required death events in overall patients in the study. An Independent Data Monitoring Committee evaluated the data. The overall level of significance for the study was 0.05, with 0.049 allocated in the testing of OS, and 0.001 allocated in the testing of rPFS. Efficacy endpoints were analyzed using intent-to-treat (ITT) population that included all the patients randomized into the study. The safety analysis set comprised all patients who received at least one dose of study medication. An unstratified analysis was conducted for coprimary and secondary endpoints in the Japanese subgroup. Kaplan Meier estimates were used for the analysis of OS and rPFS. A non-stratified Cox regression model was used to estimate the hazard ratios (HR) and the associated 95% confidence interval (CI). Consistency in the efficacy and safety results between the Japanese subgroup and overall population were assessed.

Results {#hyy129s13}
=======

Patients {#hyy129s14}
--------

The data reported here are based on the clinical cut-off date (31 October 2016) for analysis of rPFS and the first interim analysis of OS. Of total 1199 patients in the LATITUDE study, 70 (5.8%) were Japanese and were randomized (1:1) to the AAP or placebo group (*n* = 35 each), Fig. [1](#hyy129F1){ref-type="fig"}. All baseline characteristics of Japanese population were mostly consistent with the overall population and were similar between two groups; except for higher mean baseline serum PSA observed in the AAP group versus placebo and slight differences in the disease locations and Gleason scores between Japanese population and overall population (Table [1](#hyy129TB1){ref-type="table"}). The median age of Japanese patients was 70 years (range: 51--82 years). The median time that the Japanese patients received the treatment was longer (AAP group: 30.98 \[range: 1.4--43.0\] months; placebo: 18.4 \[range: 3.1--39.5\] months) than the global population (AAP group: 23.98 \[range: 0.1--43.0\] months; placebo: 14.28 \[range: 0.7--42.6\] months). At the time of cut-off date, in the Japanese subgroup, 14/35 (40%) patients in the AAP group and 28/35 (80%) patients in the placebo group discontinued the study, with progressive disease being the primary reason for discontinuation (9/14 in the AAP group, 19/28 in the placebo group). Table 1.Demographics and baseline characteristics in the Japanese subgroup versus overall population (ITT population)Japanese subgroupOverall populationAAP (*n* = 35)Placebo (*n* = 35)AAP (*n* = 597)Placebo (*n* = 602)Age, years, median (range)70.0 (57--82)70 (51--80)68.0 (38--89)67.0 (33--92)Time from initial diagnosis to first dose, months, mean (SD)1.6 (0.69)1.5 (0.65)1.8 (0.73)1.9 (0.75)Disease location, *n* (%)3535596600 Bone31 (88.6)33 (94.3)580 (97.3)585 (97.5) Node19 (54.3)18 (51.4)283 (47.5)287 (47.8) Prostate mass15 (42.9)16 (45.7)151 (25.3)154 (25.7) Lungs6 (17.1)10 (28.6)73 (12.2)72 (12.0) Liver1 (2.9)2 (5.7)32 (5.4)30 (5.0) Viscera1 (2.9)018 (3.0)13 (2.2)Gleason score at initial diagnosis, *n* (%) \<7004 (0.7)1 (0.2) 71 (2.9)1 (2.9)9 (1.5)15 (2.5) 811 (31.4)11 (31.4)267 (44.7)281 (46.7) 921 (60.0)21 (60.0)280 (46.9)264 (43.9) 102 (5.7)2 (5.7)37 (6.2)41 (6.8)Bone lesions at screening, *n* (%) 01 (2.9)2 (5.7)6 (1.0)7 (1.2) 1--21 (2.9)3 (8.6)5 (0.8)10 (1.7) 3--1014 (40.0)12 (34.3)202 (33.8)208 (34.6) 11--205 (14.3)4 (11.4)109 (18.3)97 (16.1) \>2014 (40.0)14 (40.0)275 (46.1)280 (46.5)Patients with high risk at screening GS≥8 + ≥3 bone lesions32 (91.4)29 (82.9)573 (96.0)569 (94.7) GS≥8 + measurable visceral4 (11.4)9 (25.7)82 (13.7)169 (14.1) ≥3 bone lesions + measurable visceral3 (8.6)5 (14.3)84 (14.1)169 (14.1) GS≥8 + ≥3 bone lesions + measurable visceral2 (5.7)4 (11.4)71 (11.9)141 (11.8)Baseline serum PSA, ng/ml, Mean (SD)432.3 (1098.11)182.6 (363.95)263.2 (791.44)201.7 (647.81) Median (range)54.79 (0.1; 5163.9)27.61 (0.2; 1813.8)25.43 (0.0; 8775.9)23.05 (0.1; 8889.6)Baseline hemoglobin, g/l Mean (SD)132.3 (13.67)130.8 (15.63)130.5 (16.96)131.6 (17.43) Median (range)132.00 (94.0; 156.0)133.00 (99.0; 157.0)132.0 (90.0; 175.0)133.0 (89.0; 174.0)Baseline lactate dehydrogenase (U/l) Mean (SD)180.3 (32.05)185.4 (32.92)199.3 (133.11)193.6 (104.22) Median (range)175.0 (127; 264)180.0 (119; 264)177.0 (73; 2634)176.0 (67; 1444)Total treatment duration (months), median range30.98 (1.4;43.0)18.4 (3.1; 39.5)23.98 (0.1;43.0)14.28 (0.7;42.6)Patient who received subsequent therapy12 (34.3)27 (77.1)191 (32.0)322 (53.5)Patients who received life-prolonging therapy9 (25.7)23 (65.7)125 (20.9)246 (40.9) Docetaxel8 (22.9)16 (45.7)106 (17.8)187 (31.1) Enzalutamide2 (5.7)18 (51.4)30 (5.0)76 (12.6) Cabazitaxel02 (5.7)11 (1.8)30 (5.0) Radium-22301 (2.9)11 (1.8)27 (4.5) Abiraterone acetate + prednisone05 (14.3)10 (1.7)53 (8.8)Patients who received previous prostate cancer therapy3430560560 Surgery0022 (3.7)23 (3.8) Radiotherapy0019 (3.2)26 (4.3) Hormonal34 (97.1)30 (85.7)559 (93.6)558 (92.7) GnRH analog^a^29 (82.9)21 (60.0)449 (75.2)450 (74.8) Orchiectomy1 (2.9)3 (8.6)73 (12.2)71 (11.8) Anti-androgens^b^27 (77.1)26 (74.3)373 (62.5)371 (61.6) Other^c^1 (2.9)1 (2.9)7 (1.2)10 (1.7)[^1][^2][^3][^4]

Coprimary efficacy endpoints {#hyy129s15}
----------------------------

### Overall survival {#hyy129s16}

At the time of clinical cut-off, eight deaths (AAP: *n* = 3, placebo: *n* = 5) were reported in Japanese subgroup, with a median follow-up of 35.02 months (range: 2.5; 42.3). The median OS was not reached in both AAP group and placebo group in Japanese subgroup (Fig. [2](#hyy129F2){ref-type="fig"}a). The rate of OS in Japanese patients was higher among the AAP group compared with placebo (HR: 0.64; 95% CI: 0.15--2.66) and was comparable to the overall population (HR: 0.62; 95% CI: 0.51--0.76; *P* \< 0.0001) (Fig. [2](#hyy129F2){ref-type="fig"}a and [2](#hyy129F2){ref-type="fig"}b). Furthermore, the forest plots suggested a favorable treatment effect of AAP on overall survival regardless of race and ethnicity (Fig. [2](#hyy129F2){ref-type="fig"}c).

![(a) Kaplan Meier estimate of overall survival in Japanese subgroup. (b) Kaplan Meier estimate of overall survival in overall population (ITT population). (c) Forest plots of treatment effect on overall survival within racial and ethnic subgroups.](hyy129f02){#hyy129F2}

### Radiographic progression-free survival {#hyy129s17}

At the time of analysis, 23 patients (AAP: *n* = 6, placebo: *n* = 17) had radiographic progression or death in the Japanese subgroup. The median PFS was not reached in the AAP group and was 22 months in the placebo group. A reduced risk of rPFS in the Japanese patients was observed in the AAP group versus placebo (HR: 0.22; 95% CI: 0.09--0.56), which was consistent with the overall population (HR = 0.47; 95% CI: 0.39, 0.55; *P* \< 0.0001) (Fig. [3](#hyy129F3){ref-type="fig"}a and [3](#hyy129F3){ref-type="fig"}b).

![(a) Kaplan Meier estimate of radiographic progression-free survival in Japanese subgroup. (b) Kaplan Meier estimate of radiographic progression-free survival in overall population (ITT population).](hyy129f03){#hyy129F3}

Secondary efficacy endpoints {#hyy129s18}
----------------------------

In the Japanese subpopulation, treatment with AAP delayed the time to pain progression (HR, 0.68; 95% CI: 0.35, 1.33), PSA progression (HR, 0.19; 95% CI: 0.09, 0.38; Fig. [4](#hyy129F4){ref-type="fig"}a and [4](#hyy129F4){ref-type="fig"}b), time to initiation of chemotherapy (HR, 0.43; 95% CI, 0.18--1.01) and time for the subsequent prostate cancer therapy (HR, 0.28; 95% CI, 0.14--0.55) when compared with placebo (Table [2](#hyy129TB2){ref-type="table"}). However, the AAP treatment did not reduce the risk of skeletal-related events (HR, 2.41; 95% CI: 0.82--7.05). In the overall population, there was a significantly improved outcome in all secondary endpoints in the AAP group versus placebo (Table [2](#hyy129TB2){ref-type="table"}).

![(a) Kaplan Meier estimate of time to PSA progression in Japanese subgroup. (b) Kaplan Meier estimate of time to PSA progression in overall population (ITT population).](hyy129f04){#hyy129F4}

###### 

Secondary efficacy endpoints in the Japanese subgroup versus overall population (ITT population)

  Endpoints (months)                                   Japanese subgroup  Overall population                                    
  --------------------------------------------------- ------------------- -------------------- ------------------ ------ ------ ---------------------------------
  Median time to pain progression                             NR          10.15                0.68 (0.35,1.33)   NR     16.6   0.70 (0.58;0.83); *P* \< 0.0001
  Median time to PSA progression                              NR          9.26                 0.19 (0.09,0.38)   33.2   7.4    0.30 (0.26;0.35); *P* \< 0.0001
  Median time to next skeletal-related event                  NR          NR                   2.41 (0.82,7.06)   NR     NR     0.70 (0.54;0.92); *P* = 0.0086
  Median time to chemotherapy                                 NR          35.55                0.43 (0.18,1.02)   NR     38.9   0.44 (0.35;0.56); *P* \< 0.0001
  Median time to subsequent prostate cancer therapy           NR          18.56                0.28 (0.14,0.56)   NR     21.6   0.42 (0.35;0.50); *P* \< 0.0001

AAP, abiraterone acetate plus prednisone; NR, not reached; PSA, prostate-specific antigen.

Overall, the treatment effect of AAP in Japanese subgroup, in terms of coprimary endpoints and most of the secondary efficacy endpoints, was consistent with that of the overall population.

Safety {#hyy129s19}
------

The overall incidence of AEs occurred at similar frequencies between AAP group and placebo group in the Japanese subgroup (both 97% \[34/35\]) as well as in the overall population (both 93%) (Table [3](#hyy129TB3){ref-type="table"}). The most frequently reported AEs (\>20% in either AAP or placebo group) in the Japanese subgroup were hypertension (51.4% \[18/35\] vs 22.9% \[8/35\]), nasopharyngitis (37.1% \[13/35\] vs 31.4% \[11/35\]), weight increased (both 34.3% \[12/35\]), hypokalemia (34.3% \[12/35\] vs 0%), hot flush (both 31.4% \[11/35\]), back pain (28.6% \[10/35\] vs 20% \[7/35\]), hyperglycemia (22.9% \[8/35\] vs 14.3% \[5/35\]), ALT (22.9% \[8/35\] vs 31.4% \[11/35\]) and AST elevation (22.9% \[8/35\] vs 28.6% \[10/35\]) (Table [4](#hyy129TB4){ref-type="table"}). In the overall population, the most common AEs (≥20% in either AAP or placebo group) were hypertension (37% vs 22%), hypokalemia (20% vs 4%) and back pain (18% vs 20%). In the Japanese subgroup, CTCAE Grade 3 or 4 AEs were identified in 65.7% (23/35) of patients in the AAP group and 20% (7/35) in the placebo group (Table [3](#hyy129TB3){ref-type="table"}); in the overall population, 63% (374/597) were in the AAP group and 48% (287/602) in the placebo. The incidence of serious AEs in the Japanese subgroup was 17.1% (6/35) in the AAP group and 8.6% (3/35) in the placebo group; however, in the overall patients, the incidence between the AAP group and placebo group was similar (27.6% vs 24.3%, respectively). The AEs leading to treatment discontinuation were reported in 5.7% (2/35) of patients in the AAP group and 11.4% (4/35) in the placebo group in Japanese subgroup and 10.1% (61/597) of patients in the AAP group and in 12.2% (73/602) in the placebo in overall patients. Table 3.Summary of adverse events in the Japanese subgroup versus overall population (safety population)*N* (%)Japanese subgroupOverall populationAAP (*N* = 35)Placebo (*N* = 35)AAP (*N* = 597)Placebo (*N* = 602)Any AE34 (97.1)34 (97.1)558 (93.5)557 (92.5)Grade 3 or 4 AEs23 (65.7)7 (20.0)374 (62.6)287 (47.7)Any serious AEs6 (17.1)3 (8.6)165 (27.6)146 (24.3)Any AE leading to treatment discontinuation2 (5.7)4 (11.4)73 (12.2)61 (10.1)AE leading to death1 (2.9)028 (4.7)24 (4.0)AEs of special interest Grade 3 or 4 mineralocorticoid-related AEs  Hypertension12 (34.3)2 (5.7)126 (21.1)63 (10.5)  Hypokalemia4 (11.4)062 (10.4)8 (1.3)  Fluid retention/edema005 (0.8)0 Grade 3 hepatotoxicity3 (8.6)1 (2.9)46 (7.7)20 (3.3)[^5]Table 4.Summary of most common adverse events in the Japanese subgroup (safety population)Most common adverse events^a^*n* (%)AAP (*N* = 35)Placebo (*N* = 35)All gradesGrade 3Grade 4All gradesGrade 3Grade 4Hypertension18 (51.4)12 (34.3)08 (22.9)2 (5.7)0Nasopharyngitis13 (37.1)0011 (31.4)00Hypokalemia12 (34.3)3 (8.6)1 (2.9)000Weight gain12 (34.3)0012 (34.3)2 (5.7)0Hot flush11 (31.4)0011 (31.4)00Back pain10 (28.6)007 (20.0)00Hyperglycemia8 (22.9)4 (11.4)05 (14.3)1 (2.9)0ALT increased8 (22.9)1 (2.9)011 (31.4)1 (2.9)0AST increased8 (22.9)1 (2.9)010 (28.6)1 (2.9)0Insomnia5 (14.3)003 (8.6)00Rib fracture5 (14.3)001 (2.9)00Constipation4 (11.4)004 (11.4)4 (11.4)0Dental caries4 (11.4)1 (2.9)04 (11.4)2 (5.7)0Diarrhea4 (11.4)1 (2.9)04 (11.4)2 (5.7)0Vomiting4 (11.4)004 (11.4)1 (2.9)0Hematuria4 (11.4)00000Hyperbilirubinemia4 (11.4)00000[^6][^7]

Incidence of AEs of special interest, mineralocorticoid-related AEs such as hypertension and hypokalemia and corticosteroid AE (Grade 3 or 4) such as hyperglycemia (Grade 3), in the Japanese subgroup was higher in the AAP group versus the placebo group (Table [3](#hyy129TB3){ref-type="table"} and [4](#hyy129TB4){ref-type="table"}). In the overall population, a similar trend was observed only for Grade 3 or 4 hypertension and hypokalemia events (Table [3](#hyy129TB3){ref-type="table"}). Fluid retention, edema and cardiac disorders (Grade 3 or 4) were not reported in the Japanese subgroup; however, in the overall population, five (0.8%) patients reported edema. Grade 3 hepatotoxicity (including ALT increased, AST increased and hepatic function abnormal) in the Japanese subgroup was reported in 8.6% (3/35) patients in AAP group versus 2.9% (1/35) patients in the placebo; in the overall population, the incidence was 7.7% (46/597) in the AAP group versus 3.3% (20/602) in the placebo.

In the Japanese subgroup, one patient in the AAP group died due to AE of cerebral hemorrhage. In the overall population, death was reported in 28/597 (4.7%) in the AAP and 24/602 (4.0%) in the placebo; the most common reason being cardiac disorders (AAP group: 10/597 \[1.7%\] and placebo group: 6/602 \[1.0%\]).

Discussion {#hyy129s20}
==========

In this subgroup analysis of the global, Phase 3 study (LATITUDE study), the addition of AAP to ADT improved coprimary outcomes, OS and rPFS, compared with ADT alone in Japanese men with newly diagnosed mHNPC. The combination of AAP plus ADT versus placebo plus ADT also prolonged time to PSA progression, along with most of the secondary endpoints. There were no notable safety concerns identified in Japanese patients. The overall efficacy and safety findings were in line with those observed in the global population for AAP treatment ([@hyy129C26]).

The observed 36% lower relative risk of death (HR, 0.64; 95% CI: 0.15--2.66) and 78% lower relative risk of rPFS (HR: 0.22; 95% CI: 0.09--0.56), support the addition of AAP to ADT versus ADT alone in the Japanese patients with newly diagnosed mHNPC, who had at least two high-risk features. Favorable clinical outcomes were observed with AAP plus ADT despite 40.9% of patients in the placebo group and 20.9% in the AAP group receiving subsequent life-prolonging therapy, mostly docetaxel and enzalutamide (Table [1](#hyy129TB1){ref-type="table"}). In Japanese subgroup, survival benefits showed a similar trend to that of the overall population although 65.7% of the patients in the placebo and 25.7% in the AAP group, received subsequent life-prolonging therapy.

Most of the results for the secondary efficacy endpoints of time to pain progression, PSA progression, time to initiation of chemotherapy and subsequent prostate cancer therapy in Japanese subpopulation showed consistency with the results in overall patients, supporting the AAP treatment (HR \< 1.0).

The higher risk for time to next skeletal-related event in the AAP group versus the placebo in the Japanese subgroup contrasted with the findings observed in the overall population. Of five patients who experienced rib fracture in the AAP group, three patients experienced rib fracture within 6 months from the initiation of AAP treatment; and two patients reported no events related to progression of disease or symptoms. These differences in outcomes could be attributed to several factors such as relatively few events and a small number of patients in this subgroup analysis. The role of differences in ethnicity and treatment environment influencing the treatment outcomes after hormonal therapy, especially between Japanese and Western patients with prostate cancer has been previously elucidated in retrospective studies ([@hyy129C28]--[@hyy129C30]). Findings from these studies suggest that Japanese patients showed better prognosis in terms of OS rate compared with the Western populations. The precise mechanism behind these differences is unclear, but it has been argued that Japanese patients show a greater sensitivity to hormonal therapy ([@hyy129C30],[@hyy129C31]). Moreover, the Japanese population has a higher life expectancy than Westerners regardless of the disease state, and show a favorable prognosis of OS in breast cancer, renal cancer and non-small cell lung cancer ([@hyy129C32]--[@hyy129C34]).

Consistency in the OS outcome benefit was observed between patients receiving ADT monotherapy here and a prospective study (ZAPCA) involving Japanese men with mHNPC treated with 'combined androgen blockade' (CAB; bicalutamide + LH--RH agonist), despite the differences in CAB and ADT modalities ([@hyy129C35]). Available evidence suggests a possible modest survival benefit of CAB over ADT monotherapy in the treatment of metastatic prostate cancer, however some controversy still exist ([@hyy129C36]). It is also unclear if this slight benefit is advantageous as CAB showed decline in quality of life and tolerability in few studies ([@hyy129C37],[@hyy129C38]). Additionally, in a subgroup analysis of a prospective study conducted in Japanese patients, CAB treatment did not indicate superior benefits over ADT monotherapy in the D2 setting ([@hyy129C39]). Therefore, there is currently a need for novel agents for effective management of mHSPC ([@hyy129C40]) and the present study findings suggest that potential role of AAP combined with ADT in 'high-risk' mHSPC.

The safety findings observed with the AAP group in this subgroup were consistent with that of the overall study population as well as with the previous studies conducted in mCRPC patients, reporting an increased incidence of the mineralocorticoid-related AEs of hypertension and hypokalemia ([@hyy129C14]--[@hyy129C17],[@hyy129C19],[@hyy129C20]). The frequency of Grade 3 hypertension and hypokalemia in the AAP group in overall population of LATITUDE study was higher than the previous global AAP studies (COU-AA-301 and COU-AA-302) involving mCRPC patients ([@hyy129C14],[@hyy129C17]). However, the overall relative risk of hypertension (all grades) in the global LATITUDE study of AA with 5 mg/day prednisone + ADT (1.6 \[95% CI, 1.4--1.9\]) was similar to that in previous studies of 10 mg/day prednisone (COU-AA-301:1.4 \[95% CI, 0.9--2.0\]; COU-AA-302:1.6 \[95% CI, 1.2--2.1\]) ([@hyy129C41]). The potential contributing factors for the higher incidence of Grade 3 or 4 hypertension in LATITUDE versus previous studies (COU-AA-301 and -302) may include longer treatment exposure (24 months vs 8 and 13.8 months), lower prednisone dose (5 vs 10 mg/day); and use of stringent grading with CTCAE version 4.0 versus 3.0. For instance, some Grade 2 type of hypertension events in previous studies were categorized as Grade 3 in LATITUDE study. The incidence of Grade 3 hypertension, hypokalemia and hyperglycemia occurring in the AAP group was higher in the Japanese subpopulation than the overall population. It should also be noted that longer treatment exposure in Japanese subpopulation versus the overall population (34 months vs 24 months) could have contributed to the high incidence of Grade 3 AEs in this subgroup. Overall, Grade 3 hypertension, hypokalemia and hyperglycemia events were shown to be manageable in Japanese subpopulation, underscoring the need for more appropriate and timely management of AEs, especially steroid-related AEs.

In the global LATITUDE study, in addition to the survival benefits observed, AAP plus ADT has shown clinical benefits in overall patient-reported outcomes based on consistent improvement in progression of pain, fatigue, prostate cancer symptoms, functional status and overall health-related quality of life ([@hyy129C42]).

In summary, treatment with AAP and ADT resulted in improved efficacy outcomes in terms of OS and rPFS in the Japanese patients with newly diagnosed mHNPC. AAP treatment showed an acceptable safety profile in the Japanese population. The efficacy and safety results of Japanese subgroup were consistent with those of overall population of LATITUDE study. Treatment with AAP showed a positive risk--benefit balance and may serve as a new therapeutic option to improve the prognosis of Japanese men with mHNPC having high-risk characteristics.
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[^1]: BPI-SF, Brief Pain Inventory-Short Form; ECOG, Eastern Cooperative Oncology Group; GS, Gleason score; PSA, prostate-specific antigen.

[^2]: ^a^Agonist or antagonist;

[^3]: ^b^All anti-androgens were first generation antiandrogens (e.g. bicalutamide, nilutamide, flutamide, cyproterone acetate);

[^4]: ^c^Include estrogen and glucocorticoid.

[^5]: AAP, abiraterone acetate plus prednisone; AE, adverse event.

[^6]: AAP, abiraterone acetate plus prednisone; AEs, adverse events; ALT, alanine aminotransferase; AST, aspartate aminotransferase.

[^7]: ^a^Adverse events reported by CTCAE toxicity grades.
